Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Pitt et al1 have concluded in their study that eplerenone should be prescribed to all of the postacute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure. However, there are a few concerns in using eplerenone in certain populations.
During the development of heart failure, there is an activation of the renin-angiotensin-aldosterone …